Last Updated: August 8, 2026

Claims for Patent: 5,690,923

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,690,923

Title:	Stable topical retinoid compositions
Abstract:	PCT No. PCT/NL94/00151 Sec. 371 Date Dec. 28, 1995 Sec. 102(e) Date Dec. 28, 1995 PCT Filed Jul. 1, 1994 PCT Pub. No. WO95/01160 PCT Pub. Date Jan. 12, 1995Compositions for topical application to the skin are provided, which compositions comprise a retinoid in an aqueous vehicle, and further contain at least one non-ionic surfactant, wherein the non-ionic surfactant is the crystallization-preventing and stabilizing agent for said retinoid and is selected from the group consisting of polyoxyethylene mono fatty alcohol ethers, polyoxyethylene glyceryl fatty acid triesters and ethyleneoxide/propyleneoxide block copolymers.
Inventor(s):	Tom DeVringer, Antoon Van Harrewijn, Aart Muehlenbruch
Assignee:	Astellas Pharma Europe BV
Application Number:	US08/571,898
Patent Claims:	1. A composition for topical application to the skin comprising a retinoid in an aqueous vehicle said aqueous vehicle further comprising up to 5 wt % of an organic solvent, and at least one non-ionic surfactant wherein the aqueous vehicle has a pH of between 3 and 7 and the non-ionic surfactant is a crystallization preventing and stabilizing agent for said retinoid and is selected from the group consisting ofa) polyoxyethylene mono fatty alcohol ethers, b) polyoxyethylene glyceryl fatty acid triesters, and c) ethylene oxide/proclaim oxide block copolymers. 2. A composition according to claim 1 wherein the non-ionic surfactant is selected from the group consisting ofa) polyoxyethylene (4) monolaurylether, b) polyoxyethylene (25) glyceryltrioleate, and c) SYNPERONIC PE/L44, a liquid ethyleneoxide/propyleneoxide block copolymer containing 40% of ethyleneoxide and 60% of propyleneoxide and having a molecular weight of 2.000-3.000 respectively. 3. A composition according to claim 1 comprising a further non-ionic surfactant chosen from the group of polyoxyethylene glycerin fatty acid monoesters. 4. Composition according to claim 4 wherein the polyoxyethylene glycerin fatty acid monoester is polyoxyethylene (15) glycerin monolaurate. 5. A composition according to claim 1 wherein 0-0.1 wt % of the organic solvent is present. 6. Composition according to claim 5, wherein the organic solvent is a monohydric C1 -C3 alkanol. 7. A composition according to claim 1 wherein the composition contains an antibiotic. 8. Composition according to claim 7 wherein the antibiotic is clindamycin or a derivative thereof.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.